DUSP1 and neoplasm: Many anticancer drugs regulate DUSP1 expression and immune invasion in TME; for example, sorafenib, a common drug used for HCC treatment, apart from multi-kinase inhibition, sorafenib exposure in HCC modulates anti-tumor effect via macrophages.